Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SGCAF)
| ADC Name |
BG-C477
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BG-C477
Click to Show/Hide
|
|||||
| Organization |
BeiGene (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-CEA antibody
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
2027 Update
ADC-specific functional property
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
A potent bystander effect of BG-C477 was observed in co-culture killing assay with mixed CEA-positive MKN45 and -negative HCT116 cells, indicating the potential to treat tumors with heterogeneous CEA expression.
Click to Show/Hide
|
[1]
|
References